Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05738044
Other study ID # COPD-BE
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 20, 2023
Est. completion date June 30, 2024

Study information

Verified date January 2023
Source Ruijin Hospital
Contact Jieming Qu
Phone 86-021-64370045
Email jmqu0906@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) and bronchiectasis are common chronic respiratory diseases in China. COPD is characterized by irreversible lung function decline due to airway inflammation, emphysema and alveolar destruction. Bronchiectasis is characterized by permanent bronchiectasis, its main clinical symptoms are cough, dyspnea, hemoptysis and recurrent respiratory tract infections. The incidence and prevalence of bronchiectasis have assumed continuously grows in global. Airway microbiota, whose alterations play an important role in the occurrence and development of bronchiectasis, form a complex ecosystem interacted with host cells and various biotic and abiotic factors in the microenvironment. Additionally, mounting evidence suggests that the airway microbiome is associated with COPD phenotypes and endotypes, and that dysbiosis contributes to airway inflammation. However, the mechanisms remain poorly understood, owing to limited knowledge of microbial functional properties, metabolic activities and cross-talk with the host immune system. The investigators aim to collect sputum specimen and perform multi-omic analysis on patients with COPD and bronchiectasis in seven clinical centres in China.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date June 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients diagnosed with bronchiectasis (according to the Chinese consensus, patient's previous chest CT examination must show bronchiectasis) or COPD (according to GOLD 2022). - Patients with age =18 years old. - Written informed consent. Exclusion Criteria: - Pregnancy or lactation, or those without taking effective contraceptive measures - Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders - Subjects with a history of alcohol or illicit drug abuse - Subjects with any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, acute exacerbation of chronic bronchitis or extremely severe COPD - Diagnosis of chronic gastrointestinal disease, heart disease, diabetes, severe renal insufficiency (GFR < 30ml/min) or immunodeficiency - Participated in any interventional clinical trial within 3 months before enrolment. - Poor compliance or inability to cooperate as judged by the doctor

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
No intervention

Locations

Country Name City State
China Ruijin Hospital, Medical School of Shanghai Jiaotong University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of lung microbiome in COPD and bronchiectasis patient between exacerbation and clinically stable stage The lung microbiome of COPD and bronchiectasis patients will be defined from sputum samples using traditional bacterial culture and 16S rRNA sequencing. Day0 and week 10
Secondary Change of lung metabolomics in COPD and bronchiectasis patient between exacerbation and clinically stable stage The lung microbiome of COPD and bronchiectasis patients will be defined from sputum samples using liquid chromatography-mass spectrometry (LC-MS)-based metabolomics approach. Day0 and week 10
Secondary Change of lung proteomics in COPD and bronchiectasis patient between exacerbation and clinically stable stage The lung microbiome of COPD and bronchiectasis patients will be defined from sputum samples using Olink multiplex panel. Day0 and week 10
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Recruiting NCT03250000 - Changes in Microcirculation and Functional Status During Exacerbation of COPD N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Recruiting NCT06118632 - Physiological and Environmental Data in a Remote Setting to Predict Exacerbation Events in Patients With Chronic Obstructive Pulmonary Disease
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A
Completed NCT04170361 - The Effect of Incentive Spirometry Added to Routine Physiotherapy Program on Hemodynamic Responses and Hospital Stay in Patients With COPD Exacerbation N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Not yet recruiting NCT03296215 - Pattern of Admitted Cases in Respiratory Intensive Care Unit at Assiut University Hospitals N/A
Completed NCT03003702 - Domiciliary Monitoring to Predict Exacerbations of COPD N/A
Completed NCT02912689 - NIV - NAVA vs NIV - PS for COPD Exacerbation N/A
Recruiting NCT02264483 - Low-dose CT for Diagnosis of Pneumonia in COPD Exacerbations and Comparison of the Inflammatory Profile. N/A
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Recruiting NCT02065921 - Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort
Completed NCT04880486 - Weight Training With VR in Out-Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I
Recruiting NCT04638920 - Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
Not yet recruiting NCT05897125 - Telehealth Education Leveraging Electronic Transitions Of Care for COPD Patients N/A